{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:53:44Z","timestamp":1790913224793,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012532","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000}}],"reference-count":80,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012532.pub2","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T06:44:35Z","timestamp":1736318675000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Anti-PD-1 and anti-PD-L1 antibodies for glioma"],"prefix":"10.1002","volume":"2025","author":[{"given":"Suely M","family":"de Melo","sequence":"additional","affiliation":[{"name":"Departamento de Neurocirurgia; Escola Paulista de Medicina (EPM), Universidade Federal de Sao Paulo (UNIFESP); S\u00e3o Paulo Brazil"},{"name":"Neuro Oncologia; Hospital do Cora\u00e7\u00e3o de S\u00e3o Paulo; S\u00e3o Paulo Brazil"},{"name":"Sa\u00fade Baseada em Evid\u00eancias, Escola Paulista de Medicina, Universidade Federal de S\u00e3o Paulo; S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio EN","family":"Elias Nunes da Silva","sequence":"additional","affiliation":[{"name":"Sa\u00fade Baseada em Evid\u00eancias, Escola Paulista de Medicina, Universidade Federal de S\u00e3o Paulo; S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Regina","family":"Torloni","sequence":"additional","affiliation":[{"name":"Cochrane Brazil; S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Riera","sequence":"additional","affiliation":[{"name":"N\u00facleo de Ensino e Pesquisa em Sa\u00fade Baseada em Evid\u00eancias e Avalia\u00e7\u00e3o Tecnol\u00f3gica em Sa\u00fade (NEP-Sbeats) ; Universidade Federal de S\u00e3o Paulo; S\u00e3o Paulo Brazil"},{"name":"Cochrane Afilliate Rio de Janeiro;  Petr\u00f3polis Brazil"},{"name":"Center of Health Technology Assessment; Hospital S\u00edrio-Liban\u00eas; S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"De Cicco","sequence":"additional","affiliation":[{"name":"Glioma patient; Santos Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina OC","family":"Latorraca","sequence":"additional","affiliation":[{"name":"Cochrane Brazil; S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Carolina Pereira Nunes","family":"Pinto","sequence":"additional","affiliation":[{"name":"Sa\u00fade Baseada em Evid\u00eancias, Escola Paulista de Medicina, Universidade Federal de S\u00e3o Paulo; S\u00e3o Paulo Brazil"},{"name":"Cochrane Brazil; S\u00e3o Paulo Brazil"},{"name":"Iberoamerican Cochrane Centre - Biomedical Research Institute Sant Pau (IIB Sant Pau); Barcelona Spain"},{"name":"Departamento de Ci\u00eancias Biol\u00f3gicas e da Sa\u00fade, Universidade Federal do Amap\u00e1; Macap\u00e1 Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"10.1002\/14651858.CD012532.pub2-BIB0001|cit1","doi-asserted-by":"crossref","unstructured":"Ahluwalia M Peereboom D Schilero C Forst D Wong E Wen P RBTT-01. Randomized phase 2 open label study of nivolumab plus standard dose bevacizumab versus nivolumab plus low dose bevacizumab in recurrent glioblastoma Neuro-Oncology 2018 20 Suppl 6 vi234","DOI":"10.1093\/neuonc\/noy148.971"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD012532.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"vi52","DOI":"10.1200\/JCO.2021.39.15_suppl.2015","article-title":"Randomized phase II open label study of nivolumab plus standard dose bevacizumab vs nivolumab plus low dose bevacizumab in recurrent glioblastoma (RGBM). Nivolumab Benefits Older Population","volume":"23","author":"Ahluwalia","year":"2021","journal-title":"Neuro-Oncology"},{"issue":"15_suppl","key":"10.1002\/14651858.CD012532.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1200\/JCO.2021.39.15_suppl.2015","article-title":"Randomized phase 2 study of nivolumab (nivo) plus either standard or reduced dose bevacizumab (bev) in recurrent glioblastoma (rGBM)","volume":"39","author":"Ahluwalia","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0004|cit4","unstructured":"Nivolumab plus standard dose bevacizumab versus nivolumab plus low dose bevacizumab in GBM clinicaltrials.gov\/study\/NCT03452579"},{"issue":"3","key":"10.1002\/14651858.CD012532.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nature Medicine"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0006|cit6","doi-asserted-by":"crossref","unstructured":"Orpilla J Mochizuki A Reynoso J Akkad N Lee A Davidson T ATIM-25. Neoadjuvant PD-1 antibody blockade is associated with focal upregulation of PD-L1 and CD8 T cell infiltrate in recurrent glioblastoma Neuro-Oncology 2018 20 Suppl 6 vi6","DOI":"10.1093\/neuonc\/noy148.020"},{"issue":"11","key":"10.1002\/14651858.CD012532.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro-Oncology"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0008|cit8","unstructured":"An Investigational Immuno-therapy study of temozolomide plus radiation therapy with nivolumab or placebo, for newly diagnosed patients with glioblastoma (GBM, a malignant brain cancer) (CheckMate548) clinicaltrials.gov\/study\/NCT02667587"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0009|cit9","doi-asserted-by":"crossref","unstructured":"Weller M Lim M Idbaih A Steinbach J Finocchiaro G Raval R A randomized phase 3 study of nivolumab or placebo combined with radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma with methylated MGMT promoter: Checkmate 548 Neuro-Oncology 2021 23 Suppl 6 vi55 vi56","DOI":"10.1093\/neuonc\/noab196.217"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0010|cit10","unstructured":"Pembrolizumab +\/- bevacizumab for recurrent GBM clinicaltrials.gov\/study\/NCT02337491"},{"issue":"4","key":"10.1002\/14651858.CD012532.pub2-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-20-2500","article-title":"Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for patients with recurrent glioblastoma","volume":"27","author":"Nayak","year":"2021","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0012|cit12","unstructured":"An Investigational immuno-therapy study of nivolumab compared to temozolomide, each given with radiation therapy, for newly-diagnosed patients with glioblastoma (GBM, a malignant brain cancer) (CheckMate 498) clinicaltrials.gov\/study\/NCT02617589"},{"issue":"1","key":"10.1002\/14651858.CD012532.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase 3 trial","volume":"25","author":"Omuro","journal-title":"Neuro Oncology"},{"issue":"15_suppl","key":"10.1002\/14651858.CD012532.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"TPS2079","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS2079","article-title":"A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498","volume":"34","author":"Sampson","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0015|cit15","doi-asserted-by":"crossref","unstructured":"Lim M Omuro A Vlahovic G Nivolumab (nivo) in combination with radiotherapy (RT) temozolomide (TMZ): Updated safety results from CheckMate 143 inpts with methylated or unmethylated newly diagnosed glioblastoma(GBM) Annals of Oncology 2017 28(Supplement 5) v109","DOI":"10.1093\/annonc\/mdx366"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0016|cit16","unstructured":"A study of the effectiveness and safety of nivolumab compared to bevacizumab and of nivolumab with or without ipilimumab in glioblastoma patients (CheckMate 143) clinicaltrials.gov\/study\/NCT02017717"},{"issue":"suppl_6","key":"10.1002\/14651858.CD012532.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"vi21","DOI":"10.1093\/neuonc\/now212.081","article-title":"ATIM-16. Nivolumab combined with radiotherapy with or without temozolomide in patients with newly diagnosed glioblastoma: results from phase 1 safety cohorts in Checkmate 143","volume":"18","author":"Omuro","year":"2016","journal-title":"Neuro-Oncology"},{"issue":"5","key":"10.1002\/14651858.CD012532.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/neuonc\/nox208","article-title":"Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143","volume":"20","author":"Omuro","year":"2018","journal-title":"Neuro-oncology"},{"issue":"7","key":"10.1002\/14651858.CD012532.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncology"},{"issue":"15_suppl","key":"10.1002\/14651858.CD012532.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1200\/JCO.2016.34.15_suppl.2014","article-title":"Safety and activity of nivolumab (nivo) monotherapy and nivo in combination with ipilimumab (ipi) in recurrent glioblastoma (GBM): Updated results from checkmate-143","volume":"34","author":"Reardon","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"15_suppl","key":"10.1002\/14651858.CD012532.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"TPS2101","DOI":"10.1200\/jco.2014.32.15_suppl.tps2101","article-title":"Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM)","volume":"32","author":"Sampson","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD012532.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/noajnl\/vdad124","article-title":"NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma","volume":"5","author":"Sim","journal-title":"Neuro-Oncology Advances"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0023|cit23","first-page":"1","article-title":"A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed elderly patients with glioblastoma","volume":"5","author":"Lwin","year":"2022","journal-title":"Neuro-Oncology"},{"issue":"5","key":"10.1002\/14651858.CD012532.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"v65","DOI":"10.1093\/neuonc\/noad179.0259","article-title":"CTIM-19. Oncolytic dnx-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1\/2 trial","volume":"25","author":"Nassiri","year":"2023","journal-title":"Neuro-Oncology"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0025|cit25","unstructured":"Neoadjuvant with continued adjuvant anti-PD-1 antibody versus adjuvant anti-PD-1 alone in treating newly diagnosed resectable glioblastoma: a prospective randomized controlled clinical study https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2000031405"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0026|cit26","unstructured":"A Phase I study of a personalized neoantigen cancer vaccine with radiotherapy plus pembrolizumab\/MK-3475 among newly diagnosed glioblastoma patients https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02287428"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0027|cit27","unstructured":"Phase I study of ipilimumab, nivolumab, and the combination in patients with newly diagnosed glioblastoma https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02311920"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0028|cit28","unstructured":"A Phase II, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent malignant glioma with tremelimumab and durvalumab (MEDI4736) alone and in combination to determine immunologic changes from treatment https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02794883"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0029|cit29","unstructured":"A pilot surgical trial to evaluate early immunologic pharmacodynamic parameters for the PD-1 checkpoint inhibitor, pembrolizumab (MK-3475), in patients with surgically accessible recurrent\/\u200bprogressive glioblastoma https:\/\/clinicaltrials.gov\/study\/NCT02852655"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0030|cit30","unstructured":"Phase I\/II study of laser interstitial thermotherapy (LITT) combined with checkpoint inhibitor for recurrent GBM (RGBM) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03277638"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0031|cit31","unstructured":"A multicenter, open-label phase 2 study of lenvatinib (E7080\/MK-7902) plus pembrolizumab (MK-3475) in previously treated subjects with selected solid tumors (LEAP-005) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03797326"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0032|cit32","unstructured":"A phase 1 study to evaluate IL13R\u03b12-targeted chimeric antigen receptor (CAR) T cells combined with checkpoint inhibition for patients with resectable recurrent glioblastoma https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04003649"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0033|cit33","unstructured":"A randomised phase II study of NivolUmab and Temozolomide vs Temozolomide Alone in Newly Diagnosed Elderly patients with Glioblastoma (NUTMEG) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04195139"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"v65","DOI":"10.1093\/neuonc\/noad179.0258","article-title":"CTIM-18. NRG oncology study bn007:randomized phase ii\/iii trial ofipilimiumab (IPI) plus nivolumab(NIVO) vs. temozolomide (TMZ) inmgmt-unmethylated (UMGMT)newly diagnosed glioblastoma(NGBM)","volume":"25","author":"Lassman","year":"2023","journal-title":"Neuro-Oncology"},{"issue":"Supplement_2","key":"10.1002\/14651858.CD012532.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"ii2","DOI":"10.1093\/neuonc\/noad137.005","article-title":"PL02.3.A nrg oncology study bn007:randomized phase ii\/iii trial ofipilimiumab (ipi) plus nivolumab(nivo) vs. temozolomide (tmz) inmgmt-unmethylated (umgmt)newly diagnosed glioblastoma(NGBM)","volume":"25","author":"Lassman","year":"2023","journal-title":"Neuro-Oncology"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0036|cit36","unstructured":"A phase Ib clinical trial to evaluate early immunologic pharmacodynamic parameters following neoadjuvant anti-PD-1 (Nivolumab), or the combination of anti-PD-1 plus anti-CTLA-4 (Nivolumab Plus Ipilimumab) in patients with surgically accessible glioblastoma https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04606316"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0037|cit37","unstructured":"Testing the addition of the immune therapy drugs, tocilizumab and atezolizumab, to radiation therapy for recurrent glioblastoma https:\/\/clinicaltrials.gov\/study\/NCT04729959"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0038|cit38","unstructured":"Neoadjuvant PD-1 antibody alone or combined with DC vaccines for recurrent glioblastoma https:\/\/clinicaltrials.gov\/study\/NCT04888611"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0039|cit39","unstructured":"Study of vorasidenib and pembrolizumab combination in recurrent or progressive enhancing IDH-1 mutant glioma https:\/\/clinicaltrials.gov\/study\/NCT05484622"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"2205\u201315","DOI":"10.1007\/s10147-021-02028-1","article-title":"Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open-label, non-comparative study","volume":"26","author":"Aoki","year":"2021","journal-title":"International Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD012532.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/neuonc\/nou307","article-title":"Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma","volume":"17","author":"Berghoff","year":"2015","journal-title":"Neuro-Oncology"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0042|cit42","unstructured":"Good practice data extraction form. EPOC resources for review authors, 2017 epoc.cochrane.org\/epoc-resources-review-authors (accessed 15 February 2020)"},{"issue":"4","key":"10.1002\/14651858.CD012532.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/neuonc\/noz185","article-title":"Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages","volume":"22","author":"Groot","year":"2020","journal-title":"Neuro-Oncology"},{"issue":"2","key":"10.1002\/14651858.CD012532.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0028","article-title":"Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas","volume":"1","author":"Doucette","year":"2013","journal-title":"Cancer Immunology Research"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0045|cit45","unstructured":"FDA Drug Approvals www.fda.gov\/drugs\/informationondrugs\/approveddrugs"},{"issue":"32","key":"10.1002\/14651858.CD012532.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","article-title":"Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial","volume":"31","author":"Gilbert","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0047|cit47","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2021"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0048|cit48","unstructured":"Higgins JPT Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0049|cit49","doi-asserted-by":"crossref","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from training.cochrane.org\/handbook\/archive\/v6.1","DOI":"10.1002\/9781119536604"},{"issue":"3","key":"10.1002\/14651858.CD012532.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","article-title":"A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma","volume":"25","author":"Huang","year":"2019","journal-title":"Nature Medicine"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO Journal"},{"issue":"4","key":"10.1002\/14651858.CD012532.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1084\/jem.20051776","article-title":"Tissue expression of PD-L1 mediates peripheral T cell tolerance","volume":"203","author":"Keir","year":"2006","journal-title":"Journal of Experimental Medicine"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","article-title":"Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma","volume":"27","author":"Kreisl","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD012532.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/2046-4053-2-81","article-title":"Assessing and presenting summaries of evidence in Cochrane Reviews","volume":"23","author":"Langendam","year":"2013","journal-title":"Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD012532.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"e1581530","DOI":"10.1080\/2162402X.2019.1581530","article-title":"Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome","volume":"8","author":"Liu","year":"2019","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1002\/14651858.CD012532.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","article-title":"The 2007 WHO classification of tumours of the central nervous system","volume":"114","author":"Louis","year":"2007","journal-title":"Acta Neuropathologica"},{"issue":"6","key":"10.1002\/14651858.CD012532.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathologica"},{"issue":"1","key":"10.1002\/14651858.CD012532.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1038\/s41467-021-24293-4","article-title":"Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1","volume":"12","author":"Lu","year":"2021","journal-title":"Nature Communication"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/2046-4053-3-82","article-title":"A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation","volume":"3","author":"Meader","year":"2014","journal-title":"Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD012532.pub2-BIB0060|cit60","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012532","article-title":"Immune checkpoint blockade for glioma","author":"Melo","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD012532.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.4049\/jimmunol.1700643","article-title":"PD-1 blockade promotes epitope spreading in anticancer CD8","volume":"199","author":"Memarnejadian","year":"2017","journal-title":"Journal of Immunology"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0062|cit62","unstructured":"National Cancer Institute Common terminology criteria for adverse events (v5.0) ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50"},{"issue":"2","key":"10.1002\/14651858.CD012532.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/neuonc\/nov172","article-title":"PD-L1 expression and prognostic impact in glioblastoma","volume":"18","author":"Nduom","year":"2016","journal-title":"Neuro-Oncology"},{"issue":"15","key":"10.1002\/14651858.CD012532.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S1470-2045(15)00088-1","article-title":"Immunotherapy response assessment in neuro-oncology: a report of the RANO working group","volume":"16","author":"Okada","year":"2015","journal-title":"Lancet Oncology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD012532.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016","volume":"21","author":"Ostrom","year":"2019","journal-title":"Neuro-Oncology"},{"issue":"21","key":"10.1002\/14651858.CD012532.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012532.pub2-BIB0067|cit67","first-page":"1603","article-title":"Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy","volume":"17","author":"Prins","year":"2010","journal-title":"American Association for Cancer Research"},{"issue":"17","key":"10.1002\/14651858.CD012532.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1158\/1078-0432.CCR-19-4110","article-title":"Anti-PD-1 induces M1 polarization in the glioma microenvironment and exerts therapeutic efficacy in the absence of CD8 cytotoxic T cells","volume":"26","author":"Rao","year":"2020","journal-title":"Clinical Cancer Research"},{"issue":"10","key":"10.1002\/14651858.CD012532.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/cncr.33378","article-title":"Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1","volume":"127","author":"Reardon","year":"2021","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0071|cit71","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41591-018-0339-5","article-title":"Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma","volume":"25","author":"Schalper","year":"2019","journal-title":"Nature Medicine"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0073|cit73","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Guyatt GH Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from training.cochrane.org\/handbook\/archive\/v6.1"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0074|cit74","volume-title":"EORTC QLQ-C30 Reference Values","author":"Scott","year":"2008"},{"issue":"6","key":"10.1002\/14651858.CD012532.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ejca.2010.01.012","article-title":"An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients","volume":"46","author":"Taphoorn","year":"2010","journal-title":"European Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD012532.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0077|cit77","unstructured":"World Health Organization International agency for research on cancer. GLOBOCAN 2020: cancer statistics for the year 2020: an overview https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.33588"},{"issue":"17","key":"10.1002\/14651858.CD012532.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1158\/1078-0432.CCR-17-1846","article-title":"T-Cell exhaustion signatures vary with tumor type and are severe in glioblastoma","volume":"24","author":"Woroniecka","year":"2018","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD012532.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/neuonc\/nop019","article-title":"Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma","volume":"12","author":"Wu","year":"2010","journal-title":"Neuro-Oncology"},{"issue":"3","key":"10.1002\/14651858.CD012532.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41591-019-0349-y","article-title":"Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma","volume":"25","author":"Zhao","year":"2019","journal-title":"Nature Medicine"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:02:34Z","timestamp":1790910154000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012532.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012532.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]}}}